| Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment | | |
| Immunotherapy in biliary tract cancers: Current evidence and future perspectives | | 2022 |
| Lenvatinib in patients with unresectable hepatocellular carcinoma who progressed to Child-Pugh B liver function | | 2022 |
| Dynamic Prediction of Survival After Curative Resection of Intrahepatic Cholangiocarcinoma: A Landmarking-Based Analysis | Annals of Surgical Oncology | |
| Recurrence of Hepatocellular Carcinoma After Complete Radiologic Response to Trans-Arterial Embolization: A Retrospective Study on Patterns, Treatments, and Prognoses | Annals of Surgical Oncology | |
| Evaluation of abnormal gallbladder imaging findings: Surgical management and pathologic correlations in early‐stage gallbladder cancer | Clinical Case Reports (discontinued) | 2022 |
| The second Mexican consensus on hepatocellular carcinoma. Part II: Treatment | Revista De Gastroenterología De México (English Edition) | 2022 |
| Impact of bodyweight‐based starting doses on the safety and efficacy of lenvatinib in primarily Japanese patients with hepatocellular carcinoma | Hepatology Research | |
| The Increasing Role of CT-Guided Cryoablation for the Treatment of Liver Cancer: A Single-Center Report | Cancers | 2022 |
| The Therapeutic Role of PNU-74654 in Hepatocellular Carcinoma May Involve Suppression of NF-κB Signaling | Medicina (Lithuania) | 2022 |
| Proton Therapy in the Management of Hepatocellular Carcinoma | Cancers | 2022 |
| PET-CT in Clinical Adult Oncology: III. Gastrointestinal Malignancies | Cancers | 2022 |
| II Consenso mexicano de carcinoma hepatocelular. Parte II: tratamiento | Revista De Gastroenterología De México | 2022 |
| Current Perspectives on the Surgical Management of Perihilar Cholangiocarcinoma. | Cancers | 2022 |
| In Reply to Nguyen et al. | Practical Radiation Oncology | 2022 |
| Liver-Directed Concurrent Chemoradiotherapy versus Sorafenib in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis | Cancers | 2022 |
| Indirect Comparisons via Sorafenib for the Comparative Effectiveness of Two PD-1/PD-L1 Inhibitors to Treat Advanced Hepatocellular Carcinoma Patients without Prior Systemic Therapies. | Clinical Epidemiology | 2022 |
| The Significance of Systemic Inflammation Markers in Intrahepatic Recurrence of Early-Stage Hepatocellular Carcinoma after Curative Treatment. | Cancers | 2022 |
| Ablative liver radiotherapy for unresected intrahepatic cholangiocarcinoma: Patterns of care and survival in the United States. | Cancer | 2022 |
| The Implications of Treatment Delays in Adjuvant Therapy for Resected Cholangiocarcinoma Patients. | Journal of Gastrointestinal Cancer | 2022 |
| Association of County-Level Upward Economic Mobility with Stage at Diagnosis and Receipt of Curative-Intent Treatment among Patients with Hepatocellular Carcinoma. | Annals of Surgical Oncology | 2022 |
| Precision Medicine Targeting Genomic Alterations in Advanced Cholangiocarcinoma: Current State and Future Perspectives. | Frontiers in Oncology | 2022 |
| Rapidly Evolving Landscape and Future Horizons in Hepatocellular Carcinoma in the Era of Immuno-Oncology. | Frontiers in Oncology | 2022 |
| ASO Author Reflections: Usage of Hepatic Arterial Infusion Pump Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma. | Annals of Surgical Oncology | 2022 |
| Impact of the Cancer and Aging Research Group score and treatment intensity on survival and toxicity outcomes in older adults with advanced noncolorectal gastrointestinal cancers. | Cancer | 2022 |
| Neoadjuvant and Adjuvant Therapy in Intrahepatic Cholangiocarcinoma | Journal of Clinical and Translational Hepatology | 2022 |
| Metabolism-Associated Gene Signatures for FDG Avidity on PET/CT and Prognostic Validation in Hepatocellular Carcinoma. | Frontiers in Oncology | 2022 |
| Liver-Directed Treatment Options Following Liver Tumor Recurrence: A Review of the Literature. | Frontiers in Oncology | 2022 |
| Liver Transplantation for intrahepatic cholangiocarcinoma: ready for prime time? | Hepatology | 2021 |
| Benchmarking Outcomes after Ablative Radiotherapy for Molecularly Characterized Intrahepatic Cholangiocarcinoma. | Journal of Personalized Medicine | 2021 |
| Survival following liver transplantation for locally-advanced, unresectable intrahepatic cholangiocarcinoma | American Journal of Transplantation | 2021 |
| Multimarker Panels for Detection of Early Stage Hepatocellular Carcinoma: A Prospective, Multicenter, Case-Control Study | Hepatology Communications | 2021 |
| Focal neuroendocrine carcinoma mixed with adenocarcinoma of the gallbladder with aggressive lymph node metastasis in a patient who did not meet the mixed neuroendocrine-non-neuroendocrine neoplasm criteria | Clinical Journal of Gastroenterology | 2021 |
| Surgical management of intrahepatic cholangiocarcinoma | Expert Review of Anticancer Therapy | 2021 |
| External Beam Radiation Therapy for Primary Liver Cancers: An ASTRO Clinical Practice Guideline | Practical Radiation Oncology | 2021 |
| Patterns of Recurrence and Its Effective Treatment | | 2020 |
| Benign and Malignant Tumors of the Liver | | 2020 |
| Locoregional Therapies for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis | Cancers | 2021 |
| Systemic therapy of hepatocellular carcinoma: reality and prospects | Annals of HPB Surgery | 2020 |
| Lenvatinib for large hepatocellular carcinomas with portal trunk invasion: Two case reports | World Journal of Clinical Cases | 2020 |
| Regional Therapies in Hepatocellular Carcinoma and Cholangiocarcinoma | | 2020 |
| Second-line treatment of hepatocellular carcinoma: from theory to practical issues | Meditsinskiy Sovet | 2019 |
| Screening for Gastrointestinal Cancers | | 2019 |
| Gallbladder Cancer: Current and Emerging Therapies | | 2019 |
| Transarterial Therapies | | 2019 |
| Staging and Prognosis | | 2019 |
| Hepatobiliary Malignancies | | 2018 |
| Role of Radiation Therapy in Hepatocellular Carcinoma | | 2018 |
| Liver | | |
| Benign and Malignant Tumors of the Liver | | 2017 |
| Targeted Therapies for Hepatocellular Carcinoma | | 2016 |
| Liver | | |
| Gallbladder Cancer | | 2015 |
| Hepatobiliary Cancer | | 2010 |
| Improving Outcomes of Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma: New Data and Ongoing Trials | Frontiers in Oncology | 2021 |
| Molecular genetics and targeted therapeutics in biliary tract carcinoma | World Journal of Gastroenterology | 2016 |
| Transarterial radioembolization for hepatocellular carcinoma: An update and perspectives | World Journal of Gastroenterology | 2015 |
| Glypican-3-Targeted Alpha Particle Therapy for Hepatocellular Carcinoma | Molecules | 2020 |
| Surgical Treatment of Intrahepatic Cholangiocarcinoma: Current and Emerging Principles | Journal of Clinical Medicine | 2020 |
| Comparison of the effects of adjuvant concurrent chemoradiotherapy and chemotherapy for resected biliary tract cancer | BMC Gastroenterology | 2020 |
| The effect of radiation therapy on the objective response and outcomes with nivolumab for hepatocellular carcinoma | Acta Oncológica | 2020 |
| ACR Appropriateness Criteria Chronic Liver Disease | Journal of the American College of Radiology | 2017 |
| Curative Irradiation Treatment of Hepatocellular Carcinoma: A Multicenter Phase 2 Trial | International Journal of Radiation Oncology Biology Physics | 2020 |
| Hepatocellular Carcinoma, Gallbladder Cancer, and Cholangiocarcinoma | Medical Radiology | |
| Molecular-Targeted Therapies in Hepatocellular Carcinoma | Molecular and Translational Medicine | 2019 |
| FGFR inhibitors: Emerging treatments in advanced or metastatic cholangiocarcinoma | Journal of Current Oncology | 2021 |
| Network meta-analysis of nivolumab plus ipilimumab in the second-line setting for advanced hepatocellular carcinoma | Journal of Comparative Effectiveness Research | 2021 |
| Closing the Gap in Curative Ablation of Liver Cancer | Radiology | 2021 |
| Preoperative misdiagnosis of pancreatic and periampullary cancer in patients undergoing pancreatoduodenectomy: A multicentre retrospective cohort study | European Journal of Surgical Oncology | 2021 |
| Predictors of Postoperative Liver Decompensation Events After Resection in Patients with Cirrhosis and Hepatocellular Carcinoma: A Population-Based Study | Annals of Surgical Oncology | 2021 |
| Safety and initial efficacy of ablative radioembolization for the treatment of unresectable intrahepatic cholangiocarcinoma | Oncotarget | 2021 |
| Healthcare costs related to adverse events in hepatocellular carcinoma treatment: A retrospective observational claims study | Cancer Reports | 2021 |
| Nafamostat mesilate, a nuclear factor kappa B inhibitor, enhances the antitumor action of radiotherapy on gallbladder cancer cells | PLoS ONE | 2021 |
| MiR-125b-5p Is Involved in Sorafenib Resistance through Ataxin-1-Mediated Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma | Cancers | 2021 |
| Analytical validation of a novel multi-target blood-based test to detect hepatocellular carcinoma | Expert Review of Molecular Diagnostics | 2021 |
| Concurrent Sorafenib and Radiotherapy versus Radiotherapy Alone for Locally Advanced Hepatocellular Carcinoma: A Propensity-Matched Analysis | Journal of Hepatocellular Carcinoma | 2021 |
| Camrelizumab Combined with FOLFOX4 Regimen as First-Line Therapy for Advanced Hepatocellular Carcinomas: A Sub-Cohort of a Multicenter Phase Ib/II Study | Drug Design, Development and Therapy | 2021 |
| Efficacy and safety of S-1 following gemcitabine with cisplatin for advanced biliary tract cancer | Investigational New Drugs | 2021 |
| Phase I studies of peptide vaccine cocktails derived from GPC3, WDRPUH and NEIL3 for advanced hepatocellular carcinoma | Immunotherapy | 2021 |
| Using deep learning to predict microvascular invasion in hepatocellular carcinoma based on dynamic contrast-enhanced MRI combined with clinical parameters | Journal of Cancer Research and Clinical Oncology | 2021 |
| Defining the Risk of Early Recurrence Following Curative-Intent Resection for Distal Cholangiocarcinoma | Annals of Surgical Oncology | 2021 |
| Conditional Recurrence-Free Survival after Oncologic Extended Resection for Gallbladder Cancer: An International Multicenter Analysis | Annals of Surgical Oncology | 2021 |
| The Clinical Management of Cholangiocarcinoma in the United States and Europe: A Comprehensive and Evidence-Based Comparison of Guidelines | Annals of Surgical Oncology | 2021 |
| Efficacy of First Line Systemic Chemotherapy and Multikinase Inhibitors in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis | Frontiers in Oncology | 2021 |
| Time to Rethink Upfront Surgery for Resectable Intrahepatic Cholangiocarcinoma? Implications from the Neoadjuvant Experience | Annals of Surgical Oncology | 2021 |
| Development and Validation of a Machine Learning Prognostic Model for Hepatocellular Carcinoma Recurrence After Surgical Resection | Frontiers in Oncology | 2020 |
| Recent Improvements in Racial Disparity in the Treatment of Hepatocellular Carcinoma: How Times Have Changed | Journal of Gastrointestinal Surgery | 2021 |
| Rates, Predictors, and Outcomes of Portal Lymphadenectomy for Resectable Gallbladder Cancer | Annals of Surgical Oncology | 2021 |
| Protocol for a gallbladder cancer registry study in China: the Chinese Research Group of Gallbladder Cancer (CRGGC) study | BMJ Open | 2021 |
| Prognostic significance of regional lymphadenectomy in T1b gallbladder cancer: Results from 24 hospitals in China | World Journal of Gastrointestinal Surgery | 2021 |
| The Impact of Geography in Hepatocellular Carcinoma: A Retrospective Population Based Study | Current Oncology | 2021 |
| A New Option for the Treatment of Intrahepatic Cholangiocarcinoma: Percutaneous Hepatic Perfusion with CHEMOSAT Delivery System | Cells | 2021 |
| Clinical outcomes of patients with a high alpha-fetoprotein level but without evident recurrence on CT or MRI in surveillance after curative-intent treatment for hepatocellular carcinoma | Abdominal Radiology | 2021 |
| Defining and Predicting Early Recurrence after Resection for Gallbladder Cancer | Annals of Surgical Oncology | 2021 |
| Clinical Application of Trans-Arterial Radioembolization in Hepatic Malignancies in Europe: First Results from the Prospective Multicentre Observational Study CIRSE Registry for SIR-Spheres Therapy (CIRT) | CardioVascular and Interventional Radiology | 2021 |
| Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE-240 | Cancer | 2021 |
| Late recurrence of hepatocellular carcinoma after radiofrequency ablation: a multicenter study of risk factors, patterns, and survival | European Radiology | 2021 |
| Radiofrequency ablation and stereotactic body radiotherapy for hepatocellular carcinoma: should they clash or reconcile? | International Journal of Radiation Biology | 2021 |
| Outcomes of neoadjuvant therapy for cholangiocarcinoma: A review of existing evidence assessing treatment response and R0 resection rate | Journal of Surgical Oncology | 2021 |
| Dermatologic Adverse Events Associated with Selective Fibroblast Growth Factor Receptor Inhibitors: Overview, Prevention, and Management Guidelines | Oncologist | 2021 |
